Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Business credit rating action

Sun Pharma Organon acquisition ratings boost

Analysis based on 7 articles · First reported Sep 08, 2026 · Last updated Sep 08, 2026

Sentiment
60
Attention
4
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The investment-grade ratings from Moody's and S&P signal improved creditworthiness for Sun Pharma, likely lowering its borrowing costs and supporting its ability to finance the large acquisition. The deal is expected to nearly double Sun Pharma's revenue and enhance its competitive position, which could positively influence its stock price and credit spreads.

Pharmaceuticals Financial Services

Moody s Ratings and S&P Global Ratings assigned investment-grade credit ratings to Sun Pharma Industries, India's largest pharmaceutical company, in connection with its proposed USD 11.75 billion acquisition of US-based Organon & Co. S&P assigned a preliminary 'BBB+' long-term issuer credit rating, while Moody's assigned a 'Baa1' long-term issuer rating, both with a stable outlook. The rating actions follow Sun Pharma's binding bid in April 2026 to acquire 100% of Organon at an enterprise value of USD 11.75 billion, with the transaction expected to close by March 2027 subject to regulatory approvals. The agencies expect the acquisition to nearly double Sun Pharma's revenue to about USD 14 billion by fiscal 2028 and to strengthen its scale, geographic reach, and growth platforms in women's health and biosimilars. Sun Pharma has secured a USD 12 billion committed acquisition bridge loan from a syndicate of international banks and held approximately USD 3.6 billion in cash as of March 31, 2026.

100 Sun Pharma made binding bid Organon & Co.
80 Moody s Ratings assigned rating Sun Pharma
80 S&P Global Ratings assigned rating Sun Pharma
70 Sun Pharma secured bridge loan
stock
Sun Pharma is the subject of the rating actions and the acquirer in the USD 11.75 billion Organon deal. The investment-grade ratings and expected revenue growth to about USD 14 billion by FY28 strengthen its credit profile and market position.
Importance 100.0 Sentiment 70.0
stock
Organon is the target of Sun Pharma's acquisition. The deal is expected to close by March 2027, and Organon is projected to contribute 40-45% of the combined group's EBITDA, enhancing Sun Pharma's scale and geographic reach.
Importance 90.0 Sentiment 60.0
priv
Moody's assigned a 'Baa1' investment-grade rating with a stable outlook to Sun Pharma, reflecting its assessment of the company's creditworthiness following the acquisition announcement.
Importance 60.0 Sentiment 0.0
priv
S&P assigned a preliminary 'BBB+' investment-grade rating with a stable outlook to Sun Pharma, highlighting the expected revenue growth and business strengthening from the Organon acquisition.
Importance 60.0 Sentiment 0.0
cnt
The United States is the home country of Organon, the acquisition target, and the deal involves cross-border regulatory approvals.
Importance 30.0 Sentiment 0.0
cnt
India is the home country of Sun Pharma, and the acquisition enhances the global footprint of an Indian pharmaceutical major, potentially benefiting the country's pharmaceutical sector.
Importance 30.0 Sentiment 20.0
stock
Viatris is mentioned as a comparable peer with annual revenues of USD 14-17 billion, illustrating the competitive landscape Sun Pharma will enter.
Importance 20.0 Sentiment 0.0
curr
The US dollar is the currency in which the deal value and loan amounts are denominated, but it is not directly impacted.
Importance 20.0 Sentiment 0.0
cnt
China is mentioned as a market where Organon has presence, offering Sun Pharma cross-selling opportunities, but China is not directly impacted.
Importance 15.0 Sentiment 0.0
cnt
South Korea is mentioned as a market where Organon has presence, offering Sun Pharma cross-selling opportunities, but South Korea is not directly impacted.
Importance 15.0 Sentiment 0.0
per
Kaustubh Chaubal, Senior Vice President at Moody's, commented on the acquisition's benefits, but he is not directly impacted by the event.
Importance 10.0 Sentiment 0.0
curr
The India — Indian rupee is used to express Sun Pharma's revenue estimates, but it is not directly impacted.
Importance 10.0 Sentiment 0.0
Sun Pharma related ↔ India
Moody s Ratings related ↔ India
United States strategic partners ↔ India The United States considers India a vital strategic and economic partner, actively pursuing defense and trade agreements
United States strategic rival ↔ China The United States perceives China as a strategic rival, actively implementing sanctions and export controls, while addre
India related ↔ Viatris
India strategic rivals ↔ China India perceives China as a powerful and assertive strategic rival, with whom it has ongoing territorial claims and a sig
India related ↔ South Korea
+ 1 more relationships View on Dashboard
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.